

(19)



JAPANESE PATENT OFFICE

PATENT ABSTRACTS OF JAPAN

(11) Publication number: 06072868 A

(43) Date of publication of application: 15.03.1994

(51) Int. Cl. A61K 31/20

A61K 31/23, C07C 59/42, C07C 69/587, C07C 233/09, C07F 9/10
// C07C 57/03

(21) Application number: 04227510

(22) Date of filing: 26.08.1992

(71) Applicant: MARUHA CORP

(72) Inventor: NISHIKAWA MASAZUMI
KIMURA SEIJI

(54) ANTIPSYCHOTIC AGENT

(57) Abstract:

PURPOSE: To obtain an antipsychotic agent, comprising docosahexaenoic acid (derivative) as an active ingredient and excellent in safety and therapeutic effects.

CONSTITUTION: The objective antipsychotic agent comprises one or more of docosahexaenoic acid (derivative) such as a lipxygenase metabolite as an active ingredient. Furthermore, this antipsychotic agent is perorally administered to an adult in a daily dose of preferably 300-1800mg expressed in terms of the active ingredient in the case of oral administration.

COPYRIGHT: (C)1994,JPO&Japio

XP-002092998

1/1 - (C) WPI / DERWENT
AN - 94-128761 §16!
AP - JP920227510 920826
PR - JP920227510 920826
TI - Antipsychotic agents - contain docosahexaenoic acid
(deriv)
IW - ANTIPSYCHOTIC AGENT CONTAIN ACID DERIVATIVE
PA - (TAIF) MARUHA KK
PN - JP6072868 A 940315 DW9416 A61K31/20 005pp
ORD - 1994-03-15
IC - A61K31/20 ; A61K31/23 ; C07C57/03 ; C07C59/42 ;
C07C69/587 ; C07C233/09 ; C07F9/10
FS - CPI
DC - B05
AB - J06072868 Antipsychotic agents contain one or more of
docosahexaenoic acid (I) and its derivs. as effective
component.
- (I) derivs. are fatty acids, phospholipids, or
triglycerides. (I) derivs. are salts, amides, or
esters. (I) derivs. are lipoxygenase metabolites or
their derivs. (I) derivs. are P450 dehydrogenase
metabolites or their derivs.
- The daily dose of (I) or its derivs. is 300-1800
mg/adult and 50-300 mg/adult when administered orally
or by injection, respectively.
- USE/ADVANTAGE - The agents, which are of low toxicity,
are useful in the treatment and prevention of mental
disorders.
- In an example, it was found that the action of
phencyclidine on the N-methyl-D-aspartic acid receptor
was decreased by 30 uM (I) in electrophysiological test
using rat brain cells previously treated with 5 uM
phencyclidine and 30 uM N-methyl-D-aspartic acid.
Detected lipoxygenase metabolites of (I) were 1 uM
14-hydroxy- and 1 uM 7-hydroxy-(I) and a detected P450
dehydrogenase metabolite of (I) was 1 uM
7,8-epoxydocosapentaenoic acid. The results suggested
that (I) and its metabolites may prevent or improve
psychotic diseases including schizophrenia. The
clinical efficacy of (I) was recognized in a placebo
test in that 300mg (I) ethyl ester was administered 3
times a day to 8 schizophrenic patients, 6 of them
showing improvement. (Dwg. 0/0)